Htaik Kay, Vodstrcil Lenka A, Plummer Erica L, Sfameni Amelia M, Machalek Dorothy A, Manhart Lisa E, Bradshaw Catriona S
Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia.
School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Clin Infect Dis. 2024 Jun 7. doi: 10.1093/cid/ciae295.
Differences in opinion concerning the contribution of M. genitalium to pelvic inflammatory disease (PID) has resulted in inconsistencies across global testing and treatment guidelines. We conducted a systematic review and meta-analysis to determine the association between M. genitalium and PID and M. genitalium positivity within PID cases to provide a contemporary evidence base to inform clinical practice (PROSPERO registration: CRD42022382156).
PubMed, Embase, Medline and Web of Science were searched to Dec 1, 2023 for studies that assessed women for PID using established clinical criteria and used nucleic acid amplification tests to detect M. genitalium. We calculated summary estimates of the 1) association of M. genitalium with PID (pooled odds ratio [OR]) and 2) proportion of PID cases with M. genitalium detected (pooled M. genitalium positivity in PID), using random-effects meta-analyses, with 95% confidence intervals (CI).
Nineteen studies were included: 10 estimated M. genitalium association with PID, and 19 estimated M. genitalium positivity in PID. M. genitalium infection was significantly associated with PID (pooled OR=1.67 [95%CI: 1.24-2.24]). The pooled positivity of M. genitalium in PID was 10.3% [95%CI: 5.63-15.99]. Subgroup and meta-regression analyses showed that M. genitalium positivity in PID was highest in the Americas, in studies conducted in both inpatient and outpatient clinic settings, and in populations at high risk of sexually transmitted infections.
M. genitalium was associated with a 67% increase in odds of PID and was detected in about one in ten clinical diagnoses of PID. These data support testing women for M. genitalium at initial PID diagnosis.
关于生殖支原体对盆腔炎(PID)的作用,各方观点存在差异,这导致全球检测和治疗指南不一致。我们进行了一项系统评价和荟萃分析,以确定生殖支原体与PID之间的关联以及PID病例中生殖支原体阳性情况,从而为临床实践提供当代证据基础(国际前瞻性系统评价注册库注册号:CRD42022382156)。
检索了PubMed、Embase、Medline和Web of Science数据库,截至2023年12月1日,查找那些使用既定临床标准评估女性PID并使用核酸扩增试验检测生殖支原体的研究。我们使用随机效应荟萃分析计算了以下两项汇总估计值:1)生殖支原体与PID的关联(合并比值比[OR]),以及2)检测到生殖支原体的PID病例比例(PID中生殖支原体的合并阳性率),并给出95%置信区间(CI)。
纳入了19项研究:10项评估了生殖支原体与PID的关联,19项评估了PID中生殖支原体的阳性情况。生殖支原体感染与PID显著相关(合并OR = 1.67 [95%CI:1.24 - 2.24])。PID中生殖支原体的合并阳性率为10.3% [95%CI:5.63 - 15.99]。亚组分析和荟萃回归分析表明,在美洲地区、在住院和门诊环境中开展的研究以及性传播感染高风险人群中,PID中生殖支原体的阳性率最高。
生殖支原体与PID的患病几率增加67%相关,在约十分之一的PID临床诊断中被检测到。这些数据支持在初次诊断PID时对女性进行生殖支原体检测。